{
    "clinical_study": {
        "@rank": "151267", 
        "arm_group": {
            "arm_group_label": "Ethylenediamine dihydrochloride", 
            "arm_group_type": "Experimental", 
            "description": "Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when\n      prepared using methylcellulose versus preparation using polyvinylpyrrolidone."
        }, 
        "brief_title": "Bioequivalence of Ethylenediamine Dihydrochloride Study", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Contact Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Contact", 
                "Dermatitis, Allergic Contact"
            ]
        }, 
        "detailed_description": {
            "textblock": "We propose an open, prospective, single-site study to evaluate the bioequivalence of\n      ethylenediamine dihydrochloride in methylcellulose (MC)and polyvinylpyrrolidone (PVP)\n      formulations. Bioequivalence will be determined in 15 adult subjects, with a clinical\n      history of contact dermatitis and a positive patch test (current or previous) to\n      ethylenediamine (\"sensitives\")."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current or previous symptoms and/or history consistent with allergic contact\n             dermatitis, and positive patch test (within the past 10 years) to ethylenediamine\n             dihydrochloride\n\n          -  18 years of age or older, otherwise in good health\n\n          -  Female subjects of childbearing potential must consent to a urine pregnancy test;\n             results must be negative for study inclusion.\n\n          -  Informed consent signed and understood by each subject.\n\n        Exclusion Criteria:\n\n          -  Subjects unable to meet inclusion requirements\n\n          -  Women who are breastfeeding or pregnant\n\n          -  Topical treatment during the last 7 days with corticosteroids or other\n             immunosuppressive agents on or near the test area\n\n          -  Systemic treatment during the last 7 days with corticosteroids (equivalent to > 10 mg\n             prednisone) or other immunosuppressive agents\n\n          -  Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks\n\n          -  Acute dermatitis outbreak or dermatitis on or near the test area on the back\n\n          -  Subjects unable to comply with patch test study requirements including multiple\n             return visits and activity restrictions (e.g., protecting test panels from excess\n             moisture due to showering or vigorous activity)\n\n          -  Subject participation in clinical trials of investigational drugs, treatments, or\n             devices, other than T.R.U.E. TEST, during this study or 3 weeks prior to inclusion in\n             this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798589", 
            "org_study_id": "SPD 12 P1 401"
        }, 
        "intervention": {
            "arm_group_label": "Ethylenediamine dihydrochloride", 
            "description": "1 allergen panel containing 2 allergen and 2 control patches", 
            "intervention_name": "Ethylenediamine dihydrochloride", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ethylenediamine dihydrochloride", 
        "lastchanged_date": "February 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "Dermatology Specialists PSC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations", 
        "overall_official": {
            "affiliation": "Dermatology Specialists", 
            "last_name": "Joseph Fowler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Bioequivalence will be based on concordance (or agreement) between positive reactions to ethylenediamine dihydrochloride in MC and in PVP formulations.", 
            "measure": "Primary Endpoint- Concordance between positive reactions", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the safety of the new vehicle formulations in adult subjects with known contact dermatitis (\"sensitives\") as demonstrated by a current or previous positive patch test to one (or more) of these allergens (\"sensitives\").", 
            "measure": "Secondary Endpoint-Safety of new vehicle formulations", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "source": "Allerderm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allerderm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}